Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design-Reference-Cited by-同舟云学术

Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design

Published:2020-12 Issue:6 Volume:159 Page:2013-2018.e7
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Abreu Maria T.^ORCID,Sandborn William J.,Cataldi Fabio,D'Haens Geert,Feagan Brian G.,Hanauer Stephen,Jairath Vipul,Lakatos Peter,Leptak Christopher,McGovern Dermot,Mulberg Andrew,Panes Julian,Parikh Asit,Peyrin-Biroulet Laurent,Reinisch Walter,Riddell Robert,Rubin David,Sands Bruce,Spleiss Johannes,Strauss Richard,Tole Swati,Tomaino Juli

Funder

AbbVie

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference34 articles.

1. Ulcerative colitis: Clinical trial endpoints guidance for Industry,2016

2. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity;Khanna;Aliment Pharmacol Ther,2015

3. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study;Best;Gastroenterology,1976

4. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study;Schroeder;N Engl J Med,1987

5. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development;Reinisch;Clin Gastroenterol Hepatol,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short term effectiveness of ustekinumab versus vedolizumab in Crohn’s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis;Saudi Journal of Gastroenterology;2024-08-19

2. Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study;Inflammation and Regeneration;2024-04-25

3. Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management;Alimentary Pharmacology & Therapeutics;2024-04-09

4. Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: An open-label, proof-of concept study;2024-02-28

5. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series;Journal for ImmunoTherapy of Cancer;2024-01